Novel therapeutic strategy for interstitial cystitis: clinical efficacy evaluation of combined botulinum neurotoxin type A injection into the detrusor and pelvic floor muscle trigger points

Objective This study aimed to evaluate the preliminary efficacy and safety of combined botulinum toxin type A injection into the detrusor and pelvic floor trigger points in women with interstitial cystitis/bladder pain syndrome (IC/BPS) and concomitant pelvic floor muscle dysfunction. Methods This retrospective study analyzed IC/BPS patients hospitalized at the Urology Center of the First Affiliated Hospital of Xinjiang Medical University between January 2023 and January 2025 who underwent botulinum toxin type A injection therapy. All included patients had IC/BPS with concomitant pelvic floor muscle dysfunction, defined as elevated pelvic floor electromyographic resting activity and clinically identifiable pelvic floor tenderness/trigger points. Pelvic floor muscle dysfunction was a shared eligibility characteristic of both groups and was not used to define the comparison groups. Patients were retrospectively grouped according to the treatment strategy received in routine clinical practice: intradetrusor BTX-A injection alone (Intradetrusor-only group, n = 49) or combined intradetrusor and pelvic floor trigger-point BTX-A injection (Combined-treatment group, n = 58). Pre-and post-treatment follow-up data were evaluated, including changes in ICPI, ICSI, OABSS, pain scores, Physical Health (PH) and Mental Health (MH) scores, and psychological anxiety scores. Baseline characteristics included age, BMI, history of abdominal surgery, and changes in pain intensity (FPS-R), SF-12, HARS, and OABSS. Results Among 107 patients, baseline demographic and clinical characteristics were generally comparable between the intradetrusor-only group ( n = 49) and the combined-treatment group ( n = 58), although baseline anxiety distributions differed. In adjusted linear mixed-effects models, the combined-treatment strategy was associated with greater improvement in pain intensity at 2 weeks ( β = −0.41, 95% CI −0.78 to −0.04; P = 0.029) and a more favorable OABSS trajectory at 3 months ( β = −0.74, 95% CI −1.25 to −0.23; P = 0.004). No significant adjusted between-group differences were observed for anxiety outcomes, ICPI, ICSI, or general health measures. Conclusion In women with IC/BPS and concomitant pelvic floor muscle dysfunction, both treatment strategies were associated with clinical improvement during the 3-month follow-up. The combined-treatment strategy was associated with greater improvement in selected outcomes after adjustment for baseline covariates. However, because of the retrospective, non-randomized design, potential selection and residual confounding, different intradetrusor BTX-A doses between groups, lack of placebo control, and limited follow-up, these findings are exploratory and do not establish treatment superiority.

Authors

Institutions

Publication Details

Journal
Frontiers in Surgery
Published
2026-11-17
DOI
https://doi.org/10.3389/fsurg.2026.1933425
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Novel therapeutic strategy for interstitial cystitis: clinical efficacy evaluation of combined botulinum neurotoxin type A injection into the detrusor and pelvic floor muscle trigger points

Jin Yang, Xian Ma, 张新平, Yonghui Guan et al.
Frontiers in Surgery
Urinary Bladder and Prostate Research
article

Novel therapeutic strategy for interstitial cystitis: clinical efficacy evaluation of combined botulinum neurotoxin type A injection into the detrusor and pelvic floor muscle trigger points

Jin Yang, Xian Ma, 张新平, Yonghui Guan, Cancan Wang, Cheng Luo, Yujie Wang
article en

Abstract

Objective This study aimed to evaluate the preliminary efficacy and safety of combined botulinum toxin type A injection into the detrusor and pelvic floor trigger points in women with interstitial cystitis/bladder pain syndrome (IC/BPS) and concomitant pelvic floor muscle dysfunction. Methods This retrospective study analyzed IC/BPS patients hospitalized at the Urology Center of the First Affiliated Hospital of Xinjiang Medical University between January 2023 and January 2025 who underwent botulinum toxin type A injection therapy. All included patients had IC/BPS with concomitant pelvic floor muscle dysfunction, defined as elevated pelvic floor electromyographic resting activity and clinically identifiable pelvic floor tenderness/trigger points. Pelvic floor muscle dysfunction was a shared eligibility characteristic of both groups and was not used to define the comparison groups. Patients were retrospectively grouped according to the treatment strategy received in routine clinical practice: intradetrusor BTX-A injection alone (Intradetrusor-only group, n = 49) or combined intradetrusor and pelvic floor trigger-point BTX-A injection (Combined-treatment group, n = 58). Pre-and post-treatment follow-up data were evaluated, including changes in ICPI, ICSI, OABSS, pain scores, Physical Health (PH) and Mental Health (MH) scores, and psychological anxiety scores. Baseline characteristics included age, BMI, history of abdominal surgery, and changes in pain intensity (FPS-R), SF-12, HARS, and OABSS. Results Among 107 patients, baseline demographic and clinical characteristics were generally comparable between the intradetrusor-only group ( n = 49) and the combined-treatment group ( n = 58), although baseline anxiety distributions differed. In adjusted linear mixed-effects models, the combined-treatment strategy was associated with greater improvement in pain intensity at 2 weeks ( β = −0.41, 95% CI −0.78 to −0.04; P = 0.029) and a more favorable OABSS trajectory at 3 months ( β = −0.74, 95% CI −1.25 to −0.23; P = 0.004). No significant adjusted between-group differences were observed for anxiety outcomes, ICPI, ICSI, or general health measures. Conclusion In women with IC/BPS and concomitant pelvic floor muscle dysfunction, both treatment strategies were associated with clinical improvement during the 3-month follow-up. The combined-treatment strategy was associated with greater improvement in selected outcomes after adjustment for baseline covariates. However, because of the retrospective, non-randomized design, potential selection and residual confounding, different intradetrusor BTX-A doses between groups, lack of placebo control, and limited follow-up, these findings are exploratory and do not establish treatment superiority.

Frontiers in SurgeryVol. 13
Xinjiang Medical University (CN), First Affiliated Hospital of Xinjiang Medical University (CN)
Good health and well-being
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon